Value proposition

Shaping the future of veterinary medicine through one-time therapies for major chronic pet health conditions.

Scout’s mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. By combining world-leading talent in animal health and gene therapy technology, we have built a development platform for one-time therapies that address major areas of unmet medical need in pet medicine.

We are a global company supported by leading life sciences investors and an R&D collaboration with the renowned Gene Therapy Program at the University of Pennsylvania.

About Our Currently Enrolling Study for Cats
Scout’s first therapy in development focuses on the anemia associated with chronic kidney disease (CKD) in cats. Our study is currently enrolling cats at participating clinics across the U.S. It involves a single injection (followed by 70 days of monitoring) and may relieve a cat’s anemia for life. Learn more about our study and find a participating clinic: www.scoutbio.co/catEPOstudy.


cats, dogs, Veterinary, animal health, biotechnology, and gene therapy